Hutchison China MediTech (Chi-Med) (HCM) is an innovative biopharma company focused on the highly lucrative global oncology and immunology markets. HCM has built a substantial pipeline of potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. HCM’s profitable Chinese healthcare business continues to benefit from the fast-growing domestic market. We expect progress of the mid- to late-stage pipeline durin
27 May 2016
Stellar evolution
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Stellar evolution
HUTCHMED (China) Limited (HCM:LON) | 267 -2.7 (-0.4%) | Mkt Cap: 2,326m
- Published:
27 May 2016 -
Author:
Dr Susie Jana -
Pages:
26
Hutchison China MediTech (Chi-Med) (HCM) is an innovative biopharma company focused on the highly lucrative global oncology and immunology markets. HCM has built a substantial pipeline of potential first-in-class or best-in-class tyrosine kinase inhibitor (TKI) drugs, some of which are in development with strategic partners. HCM’s profitable Chinese healthcare business continues to benefit from the fast-growing domestic market. We expect progress of the mid- to late-stage pipeline durin